Skip to main content

Table 1 Background characteristics of patients who received hepatic arterial infusion chemotherapy

From: Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial

Characteristics Median (range) or patient numbers
Age (years) 66 (32–88)
Gender (M/F) 49/6
ECOG performance status (0/1) 50/5
Etiology (HBV/HCV/others) 14/24/17
Platelet count (/mm3) 15.6 (6.4–41.4)
Total bilirubin (mg/dL) 0.9 (0.3–1.8)
Albumin (g/dL) 3.7 (2.7–5.0)
Prothrombin consumption test (%) 78 (57.4–118)
Child-Pugh score (5/6/7) 22/23/10
Number of liver tumors 5 (1–40)
Size of liver tumors (mm) 85 (18–170)
Macroscopic vascular invasion (without/with) 17/38
Vp (0–2/3–4)a 26/29
Vv (0–1/2–3) 46/9
Relative tumor size in the liver (<  50%/≥ 50%) 47/8
TACE refractory (without/with) 42/13
Extrahepatic spread (without/with) 49/6
HCC stage (III/IVa/IVb)b 30/22/3
BCLC stage (B/C)c 18/37
AFP (ng/mL) 1895.2 (2.6–529,500)
DCP (mAU/mL) 3854 (24–226,990)
  1. Abbreviations: AFP alpha-fetoprotein, DCP des-gamma-carboxy prothrombin, ECOG Eastern Cooperative Oncology Group, HBV hepatitis B virus, HCC hepatocellular carcinoma, HCV hepatitis C virus, Vp portal invasion, Vv venous invasion
  2. aVp0 through Vp4 indicated no, third branch, second branch (segmental invasion), first branch (branch invasion) and main portal vein invasion, respectively, according to Liver Cancer Study Group of Japan criteria
  3. bAccording to the Liver Cancer Group of Japan
  4. cBCLC: Barcelona Clinic Liver Cancer,